Updates from Biohaven

**MSA Study Overview**
Biohaven is conducting a randomized, placebo-controlled phase 3 study to evaluate the efficacy and safety of BHV-3241 (verdiperstat) in patients with Multiple System Atrophy (MSA).

**New Video Released**
Biohaven created a video to share more information about the pathophysiology of MSA and its potential disease-modifying treatment verdiperstat.

Timeline of Activities
- **July 31, 2019**: First person enrolled in phase 3 trial of verdiperstat in MSA
- **July 29, 2020**: MSA study completed enrollment with 336 people in the trial. 35% of patients are in the E.U. (Austria, France, Germany, Italy and UK) and 65% are in the U.S.
- **August 3, 2020**: First person enrolled in phase 3 trial of verdiperstat for ALS
- **3Q2021**: Biohaven on track to share MSA study results by third quarter 2021